Financial Release
"Our third-quarter results reflect the strong performance of our business with double-digit growth from HUMIRA and several other key brands. Our underlying business grew nearly 14 percent in the quarter excluding lipids," said
Third-Quarter Results
- Worldwide sales were
$5.019 billion in the third quarter, up 7.8 percent. On an operational basis, sales increased 8.3 percent, excluding a 0.5 percent unfavorable impact from foreign exchange rate fluctuations. Excluding sales from our lipid franchise due to the loss of exclusivity, sales increased 13.5 percent on an operational basis in the quarter. - Third-quarter sales growth was driven primarily by the continued strength of HUMIRA. Global HUMIRA sales increased 17.5 percent, or 17.8 percent on an operational basis, excluding the impact of foreign exchange rate fluctuations. Total company sales growth was also driven by strong growth from key products including Kaletra, Synthroid, Creon, Synagis and Duodopa.
- The adjusted gross margin ratio in the third quarter was 81.1 percent, excluding intangible asset amortization and other specified items, up 140 basis points versus third-quarter 2013. The gross margin ratio under U.S. generally accepted accounting principles (GAAP) was 78.2 percent.
- Adjusted selling, general and administrative (SG&A) expense was 26.4 percent of sales in the third quarter, up 9.1 percent from the prior year, reflecting continued investment in our growth brands and the expected HCV launch. On a GAAP basis, SG&A was 31.8 percent of sales.
- Adjusted research and development (R&D) was 16.2 percent of sales in the quarter, up 14.4 percent from the prior year, reflecting funding actions in support of our mid- and late-stage pipeline and the continued pursuit of additional HUMIRA indications. On a GAAP basis, R&D was also 16.2 percent of sales.
- Net interest expense was
$53 million on an adjusted basis and$128 million on a GAAP basis. The adjusted tax rate was 22.4 percent in the quarter and 26.3 percent on a GAAP basis. - Third-quarter diluted earnings per share were
$0.31 on a GAAP basis. Adjusted diluted earnings per share, excluding intangible asset amortization expense and other specified items, were$0.89 .
Key Events from the Third Quarter
- On
Oct. 20 ,AbbVie and Shire agreed to terminate their proposed merger following the decision byAbbVie's board of directors onOct. 15 to withdraw support for the proposed transaction. The Company's decision was based upon its assessment of theSept. 22, 2014 notice issued by theU.S. Department of Treasury . This notice included changes that negatively impacted the economics of the transaction. As a result, the original price for the proposed transaction could no longer be justified. The notice also introduced an unacceptable level of risk and uncertainty given the magnitude of the proposed changes and the stated intention of theDepartment of Treasury to continue to revise tax principles to further impact such transactions. - On
Oct. 20 , theAbbVie board of directors authorized a new$5 billion stock repurchase program and increased the company's quarterly cash dividend by nearly 17 percent from$0.42 per share to$0.49 per share, payable onFeb. 13, 2015 to stockholders of record as ofJan. 15, 2015 . Additionally, onSept. 19 , the board of directors declared a quarterly cash dividend of$0.42 per share, payableNov. 17, 2014 to stockholders of record at the close of business onOct. 15, 2014 . AbbVie andInfinity Pharmaceuticals entered into a global collaboration to develop and commercialize duvelisib (IPI-145), Infinity's oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma. Duvelisib has shown clinical activity across a broad range of blood cancers, including indolent non-Hodgkin lymphoma (iNHL) and chronic lymphocytic leukemia (CLL). Infinity is conducting registration-focused trials evaluating the safety and efficacy of duvelisib, including DYNAMO, a Phase 2 study in patients with iNHL, and DUO, a Phase 3 study in patients with CLL.AbbVie and Calico announced a novel R&D collaboration intended to help the two companies discover, develop and bring to market new therapies for patients with age-related diseases, including for neurodegeneration and cancer. Under the agreement, the companies will combine their complementary strengths to accelerate the availability of new therapies: Calico will use its scientific expertise to establish a world-class research and development facility, with a focus on drug discovery and early drug development; andAbbVie will provide scientific and clinical development expertise and its strong commercial execution to bring new discoveries to market.The European Medicines Agency (EMA) and theU.S. Food and Drug Administration (FDA ) granted orphan drug designation toAbbVie's investigational compound ABT-414, an anti-epidermal growth factor receptor antibody drug conjugate, which is being evaluated for safety and efficacy in patients with glioblastoma multiforme. Glioblastoma multiforme is the most common and most aggressive type of malignant primary brain tumor and has a five year survival rate of approximately 4 percent.AbbVie announced results from a Phase 3 pivotal study demonstrating that HUMIRA is effective in reducing common clinical signs and symptoms in moderate-to-severe hidradenitis suppurativa (HS), specifically the number of abscesses and inflammatory nodules. These data were presented at theEuropean Society for Dermatological Research (ESDR) meeting. Results from the PIONEER I study show that HS patients treated with HUMIRA 40 mg weekly achieved a significantly greater response versus those on placebo at week 12.AbbVie also recently presented new results from PIONEER II, a second pivotal HS study, at the 23rdCongress of theEuropean Academy of Dermatology and Venereology (EADV) meeting. The results of this study, in combination with results from PIONEER I, will contribute to worldwide regulatory filings for an expanded use of HUMIRA.AbbVie andBiogen Idec announced the full results from the Phase 3 DECIDE clinical trial, which show ZINBRYTA (daclizumab high-yield process), dosed subcutaneously once a month, demonstrated a statistically significant improvement in reducing disease activity in people with relapsing-remitting multiple sclerosis (RRMS) compared to AVONEX (interferon beta-1a). These results were presented at the Sixth Triennial Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS-ECTRIMS) inBoston . We are engaged with worldwide authorities regarding the regulatory filings for ZINBRYTA. We continue to expect the submissions to occur in the first half of 2015.- The
FDA approved HUMIRA for reducing signs and symptoms, and achieving and maintaining clinical remission, in pediatric Crohn's disease patients 6 years of age and older when certain other treatments have not worked well enough. ThisFDA approval represents the eighth indication for HUMIRA inthe United States and makes it the first and only biologic treatment approved for use in this patient population that can be administered at home. Additionally, theFDA approved the extension of the HUMIRA indication for moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) to reducing signs and symptoms in patients ages 2 and older. AbbVie announced that data from its ongoing Phase 1 through Phase 3 hepatitis C clinical development programs will be presented at the Annual Meeting of theAmerican Association for the Study of Liver Diseases (AASLD) inBoston ,November 7-11 . Abstracts will be presented highlighting results fromAbbVie's investigational treatment combining three direct-acting antivirals (ABT-450/ritonavir, ombitasvir and dasabuvir) with or without ribavirin (RBV) in patients with genotype 1 chronic HCV infection. These abstracts include a Phase 2/3 study in patients co-infected with human immunodeficiency virus type 1 (TURQUOISE-I) and a Phase 2 study in liver transplant recipients without cirrhosis (CORAL-I). Additionally, Phase 2 data will be presented from investigational studies evaluating the combination of ABT-450/ritonavir and ombitasvir with or without RBV in genotype 4 patients (PEARL-I).AbbVie will also be presenting data from its two additional pipeline HCV compounds, ABT-493 and ABT-530.AbbVie released interim results from an ongoing Phase 2 study of its investigational compound veliparib in combination with chemotherapy, which showed a 35 percent improvement in progression-free survival and a 30 percent improvement in overall survival in patients with previously untreated metastatic or advanced non-small cell lung cancer (NSCLC). These results, which evaluated veliparib as a potential treatment for metastatic or advanced NSCLC, were presented for the first time at the 2014 Annual Congress of theEuropean Society for Medical Oncology (ESMO) inMadrid, Spain .
Full-Year 2014 Outlook
Today,
About
Conference Call
Non-GAAP Financial Results
Financial results for 2013 and 2014 are presented on both a reported and a non-GAAP basis. Reported results were prepared in accordance with GAAP and include all revenue and expenses recognized during the period. Non-GAAP results adjust for certain non-cash items and for factors that are unusual or unpredictable, and exclude those costs, expenses, and other specified items presented in the reconciliation tables later in this release. AbbVie's management believes non-GAAP financial measures provide useful information to investors regarding
Forward-Looking Statements
Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements.
AbbVie Inc. Key Product Sales Quarter Ended Sept. 30, 2014 (Unaudited) |
||||||||
% Change vs. 3Q13 |
||||||||
Sales (in millions) |
International |
Total |
||||||
U.S. |
Int'l. |
Total |
U.S. |
Operational |
Reported |
Operational |
Reported |
|
TOTAL SALES |
$2,809 |
$2,210 |
$5,019 |
7.4% |
9.5% |
8.2% |
8.3% |
7.8% |
Humira |
1,739 |
1,516 |
3,255 |
25.3 |
10.3 |
9.7 |
17.8 |
17.5 |
Kaletra |
53 |
203 |
256 |
(14.1) |
19.7 |
16.5 |
10.7 |
8.4 |
AndroGel |
232 |
-- |
232 |
(6.7) |
n/a |
n/a |
(6.7) |
(6.7) |
Synthroid |
200 |
-- |
200 |
24.3 |
n/a |
n/a |
24.3 |
24.3 |
Lupron |
147 |
49 |
196 |
3.9 |
(8.4) |
(10.0) |
0.4 |
-- |
Creon |
148 |
-- |
148 |
47.6 |
n/a |
n/a |
47.6 |
47.6 |
Sevoflurane |
20 |
114 |
134 |
0.9 |
(1.1) |
(3.3) |
(0.8) |
(2.7) |
Synagis |
-- |
109 |
109 |
n/a |
18.3 |
11.9 |
18.3 |
11.9 |
Dyslipidemia |
63 |
-- |
63 |
(76.9) |
n/a |
n/a |
(76.9) |
(76.9) |
Duodopa |
-- |
56 |
56 |
n/a |
20.8 |
20.2 |
20.8 |
20.2 |
Note: "Operational" growth reflects the percentage change over the prior year excluding the impact of exchange rate fluctuations. Dyslipidemia includes sales of TriCor/Trilipix, Niaspan, Simcor and Advicor. |
n/a = not applicable |
AbbVie Inc. Key Product Sales Nine Months Ended Sept. 30, 2014 (Unaudited) |
||||||||
% Change vs. 9M13 |
||||||||
Sales (in millions) |
International |
Total |
||||||
U.S. |
Int'l. |
Total |
U.S. |
Operational |
Reported |
Operational |
Reported |
|
TOTAL SALES |
$7,681 |
$6,827 |
$14,508 |
4.3% |
9.3% |
8.1% |
6.6% |
6.1% |
Humira |
4,592 |
4,588 |
9,180 |
28.7 |
13.4 |
13.2 |
20.6 |
20.5 |
AndroGel |
704 |
-- |
704 |
(5.7) |
n/a |
n/a |
(5.7) |
(5.7) |
Kaletra |
163 |
504 |
667 |
(9.9) |
(6.6) |
(8.8) |
(7.4) |
(9.1) |
Lupron |
420 |
151 |
571 |
2.5 |
(5.7) |
(8.9) |
0.1 |
(0.8) |
Synagis |
-- |
537 |
537 |
n/a |
12.0 |
4.7 |
12.0 |
4.7 |
Synthroid |
523 |
-- |
523 |
20.8 |
n/a |
n/a |
20.8 |
20.8 |
Sevoflurane |
61 |
369 |
430 |
12.1 |
5.7 |
3.2 |
6.6 |
4.4 |
Creon |
365 |
-- |
365 |
23.2 |
n/a |
n/a |
23.2 |
23.2 |
Dyslipidemia |
224 |
-- |
224 |
(77.3) |
n/a |
n/a |
(77.3) |
(77.3) |
Duodopa |
-- |
164 |
164 |
n/a |
24.5 |
26.9 |
24.5 |
26.9 |
Note: "Operational" growth reflects the percentage change over the prior year excluding the impact of exchange rate fluctuations. Dyslipidemia includes sales of TriCor/Trilipix, Niaspan, Simcor and Advicor. |
n/a = not applicable |
AbbVie Inc. Consolidated Statements of Earnings Quarter and Nine Months Ended Sept. 30, 2014 and 2013 (Unaudited) (In millions, except per share data) |
||||||||
Third Quarter |
Nine Months |
|||||||
2014 |
2013 |
2014 |
2013 |
|||||
Net sales |
$5,019 |
$4,658 |
$14,508 |
$13,679 |
||||
Cost of products sold |
1,094 |
1,092 |
3,307 |
3,299 |
||||
Selling, general and administrative |
1,595 |
1,261 |
4,383 |
3,904 |
||||
Research and development |
812 |
714 |
2,418 |
2,057 |
||||
Acquired in-process research and development |
308 |
220 |
324 |
290 |
||||
Total operating cost and expenses |
3,809 |
3,287 |
10,432 |
9,550 |
||||
Operating earnings |
1,210 |
1,371 |
4,076 |
4,129 |
||||
Interest expense, net |
128 |
69 |
262 |
210 |
||||
Net foreign exchange loss |
174 |
11 |
182 |
40 |
||||
Other (income) expense, net |
221 |
5 |
226 |
(14) |
||||
Earnings before income tax expense |
687 |
1,286 |
3,406 |
3,893 |
||||
Income tax expense |
181 |
322 |
822 |
893 |
||||
Net earnings |
$506 |
$964 |
$2,584 |
$3,000 |
||||
Diluted earnings per share |
$0.31 |
$0.60 |
$1.60 |
$1.86 |
||||
Diluted earnings per share, excluding specified items |
$0.89 |
$0.82 |
$2.43 |
$2.32 |
a) |
|||
Average diluted shares outstanding |
1,610 |
1,605 |
1,609 |
1,602 |
a) Refer to the Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for further details. |
Note: The computation of diluted earnings per share for the quarter and nine months ended Sept. 30, 2014 and 2013 were calculated pursuant to the two-class method which requires the allocation of net earnings between common stockholders and participating security holders. |
AbbVie Inc. Reconciliation of GAAP Reported to Non-GAAP Adjusted Information Quarter Ended Sept. 30, 2014 (Unaudited) (In millions, except per share data) |
||||
1. Specified items impacted results as follows: |
||||
3Q14 |
||||
Earnings |
Diluted |
|||
Pre-tax |
After-tax |
EPS |
||
As reported (GAAP) |
$687 |
$506 |
$0.31 |
|
Adjusted for specified items: |
||||
Intangible asset amortization |
98 |
70 |
0.04 |
|
Separation costs |
109 |
98 |
0.06 |
|
Acquired IPR&D |
308 |
206 |
0.13 |
|
Calico collaboration |
250 |
250 |
0.15 |
|
Shire transaction costs |
276 |
172 |
0.11 |
|
Other |
139 |
147 |
0.09 |
|
As adjusted (non-GAAP) |
$1,867 |
$1,449 |
$0.89 |
Intangible asset amortization reflects costs recognized as a result of licensing and acquisition activities. Separation costs are expenses related to the separation of AbbVie from Abbott. Acquired IPR&D primarily reflects the upfront payment related to the Infinity collaboration. Calico collaboration reflects the upfront payment related to the recently announced Calico collaboration. Shire transaction costs are expenses related to the terminated Shire transaction. Other specified items are primarily associated with an additional year of the Branded Prescription Drug Fee as required by new IRS regulations. |
2. The impact of the specified items by line item was as follows: |
||||||||
3Q14 |
||||||||
Cost of products sold |
SG&A |
R&D |
Acquired IPR&D |
Net foreign exchange loss |
Interest expense (income) |
Other (income) expense |
||
As reported (GAAP) |
$1,094 |
$1,595 |
$812 |
$308 |
$174 |
$128 |
$221 |
|
Adjusted for specified items: |
||||||||
Intangible asset amortization |
(98) |
-- |
-- |
-- |
-- |
-- |
-- |
|
Separation costs |
(4) |
(104) |
(1) |
-- |
-- |
-- |
-- |
|
Acquired IPR&D |
-- |
-- |
-- |
(308) |
-- |
-- |
-- |
|
Calico collaboration |
-- |
-- |
-- |
-- |
-- |
-- |
(250) |
|
Shire transaction costs |
-- |
(36) |
-- |
-- |
(165) |
(75) |
-- |
|
Other |
(44) |
(129) |
-- |
-- |
-- |
-- |
34 |
|
As adjusted (non-GAAP) |
$948 |
$1,326 |
$811 |
-- |
$9 |
$53 |
$5 |
3. The adjusted tax rate for the third quarter of 2014 was 22.4 percent, as detailed below: |
3Q14 |
||||
Pre-tax |
Income |
|||
income |
Taxes |
Tax rate |
||
As reported (GAAP) |
$687 |
$181 |
26.3% |
|
Specified items |
1,180 |
237 |
20.1% |
|
As adjusted (non-GAAP) |
$1,867 |
$418 |
22.4% |
AbbVie Inc. |
|
Reconciliation of GAAP Reported to Non-GAAP Adjusted Information |
|
Quarter Ended Sept. 30, 2013 |
|
(Unaudited) (In millions, except per share data) |
|
1. Specified items impacted results as follows: |
|
3Q13 |
||||
Earnings |
Diluted |
|||
Pre-tax |
After-tax |
EPS |
||
As reported (GAAP) |
$1,286 |
$964 |
$0.60 |
|
Adjusted for specified items: |
||||
Intangible asset amortization |
137 |
98 |
0.06 |
|
Separation costs |
51 |
33 |
0.02 |
|
Acquired IPR&D |
220 |
220 |
0.13 |
|
Restructuring/Other |
14 |
12 |
0.01 |
|
As adjusted (non-GAAP) |
$1,708 |
$1,327 |
$0.82 |
Intangible asset amortization reflects costs recognized as a result of licensing and acquisition activities. Separation costs are expenses related to the separation of AbbVie from Abbott. Acquired IPR&D reflects the upfront payment related to the previously announced collaborations with Ablynx and Galapagos. Restructuring/Other is primarily associated with previously announced restructuring activities. |
2. The impact of the specified items by line item was as follows: |
||||||
3Q13 |
||||||
Cost of |
SG&A |
R&D |
Acquired |
Other |
||
As reported (GAAP) |
$1,092 |
$1,261 |
$714 |
$220 |
$5 |
|
Adjusted for specified items: |
||||||
Intangible asset amortization |
(137) |
-- |
-- |
-- |
-- |
|
Separation costs |
(4) |
(46) |
(1) |
-- |
-- |
|
Acquired IPR&D |
-- |
-- |
-- |
(220) |
-- |
|
Restructuring/Other |
(7) |
-- |
(4) |
-- |
(3) |
|
As adjusted (non-GAAP) |
$944 |
$1,215 |
$709 |
-- |
$2 |
3. The adjusted tax rate for the third quarter was 22.3 percent, as detailed below: |
3Q13 |
||||
Pre-tax |
Income |
|||
income |
taxes |
Tax rate |
||
As reported (GAAP) |
$1,286 |
$322 |
25.0% |
|
Specified items |
422 |
59 |
14.0% |
|
As adjusted (non-GAAP) |
$1,708 |
$381 |
22.3% |
AbbVie Inc. |
Reconciliation of GAAP Reported to Non-GAAP Adjusted Information |
Nine Months Ended Sept. 30, 2014 |
(Unaudited) (In millions, except per share data) |
1. Specified items impacted results as follows: |
9M14 |
||||
Earnings |
Diluted |
|||
Pre-tax |
After-tax |
EPS |
||
As reported (GAAP) |
$3,406 |
$2,584 |
$1.60 |
|
Adjusted for specified items: |
||||
Intangible asset amortization |
307 |
218 |
0.14 |
|
Separation costs |
299 |
282 |
0.17 |
|
R&D |
40 |
40 |
0.03 |
|
Acquired IPR&D |
324 |
222 |
0.14 |
|
Calico collaboration |
250 |
250 |
0.15 |
|
Shire transaction costs |
283 |
179 |
0.11 |
|
Other |
148 |
154 |
0.09 |
|
As adjusted (non-GAAP) |
$5,057 |
$3,929 |
$2.43 |
Intangible asset amortization reflects costs recognized as a result of licensing and acquisition activities. Separation costs are expenses related to the separation of AbbVie from Abbott. R&D is associated with payments for previously announced collaborations. Acquired IPR&D reflects upfront payments related to previously announced collaborations. Calico collaboration reflects the upfront payment related to the recently announced Calico collaboration. Shire transaction costs are expenses related to the terminated Shire transaction. Other is associated with restructuring activities and an additional year of the Branded Prescription Drug Fee as required by new IRS regulations. |
2. The impact of the specified items by line item was as follows: |
||||||||
9M14 |
||||||||
Cost of products sold |
SG&A |
R&D |
Acquired IPR&D |
Net foreign exchange loss |
Interest expense (income) |
Other (income) expense |
||
As reported (GAAP) |
$3,307 |
$4,383 |
$2,418 |
$324 |
$182 |
$262 |
$226 |
|
Adjusted for specified items: |
||||||||
Intangible asset amortization |
(307) |
-- |
-- |
-- |
-- |
-- |
-- |
|
Separation costs |
(10) |
(286) |
(3) |
-- |
-- |
-- |
-- |
|
R&D |
-- |
-- |
(40) |
-- |
-- |
-- |
-- |
|
Acquired IPR&D |
-- |
-- |
-- |
(324) |
-- |
-- |
-- |
|
Calico collaboration |
-- |
-- |
-- |
-- |
-- |
-- |
(250) |
|
Shire transaction costs |
-- |
(43) |
-- |
-- |
(165) |
(75) |
-- |
|
Other |
(51) |
(131) |
-- |
-- |
-- |
-- |
34 |
|
As adjusted (non-GAAP) |
$2,939 |
$3,923 |
$2,375 |
-- |
$17 |
$187 |
$10 |
3. The adjusted tax rate for the first nine months of 2014 was 22.3 percent, as detailed below: |
9M14 |
||||
Pre-tax |
Income |
|||
income |
Taxes |
Tax rate |
||
As reported (GAAP) |
$3,406 |
$822 |
24.1% |
|
Specified items |
1,651 |
306 |
18.5% |
|
As adjusted (non-GAAP) |
$5,057 |
$1,128 |
22.3% |
AbbVie Inc. |
Reconciliation of GAAP Reported to Non-GAAP Adjusted Information |
Nine Months Ended Sept. 30, 2013 |
(Unaudited) (In millions, except per share data) |
1. Specified items impacted results as follows: |
9M13 |
||||
Earnings |
Diluted |
|||
Pre-tax |
After-tax |
EPS |
||
As reported (GAAP) |
$3,893 |
$3,000 |
$1.86 |
|
Adjusted for specified items: |
||||
Intangible asset amortization |
408 |
294 |
0.18 |
|
Separation costs |
152 |
97 |
0.06 |
|
Acquired IPR&D |
290 |
290 |
0.18 |
|
Restructuring/Other |
70 |
60 |
0.04 |
|
As adjusted (non-GAAP) |
$4,813 |
$3,741 |
$2.32 |
Intangible asset amortization reflects costs recognized as a result of licensing and acquisition activities. Separation costs are expenses related to the separation of AbbVie from Abbott. Acquired IPR&D reflects the upfront payment related to previously announced collaborations. Restructuring/Other is primarily associated with previously announced restructuring activities and the impact of the Venezuelan currency devaluation. |
|
2. The impact of the specified items by line item was as follows: |
|||||||
9M13 |
|||||||
Cost of |
SG&A |
R&D |
Acquired IPR&D |
Net foreign |
Other |
||
As reported (GAAP) |
$3,299 |
$3,904 |
$2,057 |
$290 |
$40 |
($14) |
|
Adjusted for specified items: |
|||||||
Intangible asset amortization |
(408) |
-- |
-- |
-- |
-- |
-- |
|
Separation costs |
(11) |
(135) |
(6) |
-- |
-- |
-- |
|
Acquired IPR&D |
-- |
-- |
-- |
(290) |
-- |
-- |
|
Restructuring/Other |
3 |
(38) |
(15) |
-- |
(11) |
(9) |
|
As adjusted (non-GAAP) |
$2,883 |
$3,731 |
$2,036 |
-- |
$29 |
($23) |
3. The adjusted tax rate for the first nine months of 2013 was 22.3 percent, as detailed below: |
9M13 |
||||
Pre-tax |
Income |
|||
income |
taxes |
Tax rate |
||
As reported (GAAP) |
$3,893 |
$893 |
22.9% |
|
Specified items |
920 |
179 |
19.5% |
|
As adjusted (non-GAAP) |
$4,813 |
$1,072 |
22.3% |
SOURCE
Media, Jennifer Smoter, (847) 935-8865, or Adelle Infante, (847) 938-8745; or Investors, Larry Peepo, (847) 935-6722, or Liz Shea, (847) 935-2211